Filing Flows › Vertex Pharmaceuticals (VRTX) › JOURNAVX revenue
Vertex Pharmaceuticals (VRTX) JOURNAVX revenue by quarter
Vertex Pharmaceuticals' JOURNAVX revenue was $58.3M in Q3 2026 (third quarter 2026), +18% from Q2 2026. Over the last 3 quarters it ranged from $29.0M (Q1 2026) to $58.3M (Q3 2026).
| Quarter | JOURNAVX revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $58.3M | +18% | — |
| Q2 2026 | $49.6M | +71% | — |
| Q1 2026 | $29.0M | — | — |
Q3 2026 at a glance
Vertex Pharmaceuticals, Q3 2026: revenue $3.4B (+12% year over year), operating margin 20.7%, net earnings $654M, operating cash flow $643M. The chart follows the revenue to costs, profit and cash.
Questions
What is Vertex Pharmaceuticals' JOURNAVX revenue?
Vertex Pharmaceuticals' JOURNAVX revenue was $58.3M in Q3 2026 (third quarter 2026), +18% from Q2 2026.
How has Vertex Pharmaceuticals' JOURNAVX revenue changed?
Over the last 3 quarters it ranged from $29.0M (Q1 2026) to $58.3M (Q3 2026).
Q3 2026 results → · How Vertex Pharmaceuticals makes money →